AptarGroup (ATR) 9 Feb 242023 Q4 Earnings call transcript

Ladies and gentlemen, thank you for standing by. Welcome to the Aptar's 2023 Fourth Quarter Conference Call. [Operator Instructions] Introducing today's conference call is Marry Skafidas, Vice President of Investor Relations and Communications. Please go ahead.

Thank you. for us thanks and everyone, being today. with Hello,

are President Kuhn, and me Vice on of Tanda, call today's Aptar. of Bob Joining CEO Stephan Aptar; and CFO President Executive and

the deck release press posted website and slide Investor Our have page. Relations accompanying on been our under

the measures GAAP forth call, be to financial during non-GAAP for Please the are set These measure the yesterday this to press the refer non-GAAP financial earnings discussing this most and release During reconciled certain most in reconciliations release. to we call. measures discussed measures. comparable will disseminated are press directly comparable reconciliations measures GAAP of the

the we website. to Stephan. conference call also will replay a on always, And of would our I this turn call As now over post to like

and fourth We by full my and begin on joining you, appreciate I call additional year-end provide the good remarks year. the the our in Thank call, everyone. quarter details for results. you quarter today. and results morning, Bob on us Kuhn, the CFO, will will Later the highlighting our Marry,

X. Slide on Starting

in key end In systems, margin demand on cost as and management proprietary system rhinitis, grew as drug over robust central rapid more medicine, fourth for quarter, drug systems and per quarter with well allergic technologies. dispensing as margin in company such improvement XX%, due continued an driven growth as significant $X.XX improvement X-point nervous focus than of of record the EPS therapeutics achieved across a markets. the proprietary which the pharma year with For year's the increase strong strong across the was pharma prior core several finished EBITDA emergency adjusted delivery X, decongestions. the nasal to fragrance our share both for quarter. of Aptar our year sales applications X% growth by well delivery margin quarter The the We achieved a adjusted as

growth quarter. drove also results positive the Fragrance Solid from in Dispensing Solutions

of X%. Turning pharma was the About year, XX% through X declined to sales due passing full resin core growth with X% was for customers. sales beauty core costs lower to delivering closures Slide to while and the the half of of up X% for decrease closures Aptar our delivered growth,

the reminder, XXXX, a business growth. business, value with the our raising the most few with for segment. Pharma build note commercialization. taking which to of have new for pipeline-driven ready is well to pharma from new while opportunities projects of XX core equal As an X the a is adding risk-adjusted for they of to our been launches growth launches new long-term our pipeline, highest sales to be targets market since solid XXXX, It product In number anywhere years for that important sales for years, which a to continued bodes of on our once continue project underpins

full year segments. and of are Turning increase. beauty, the seeing personal segment, After opportunities and books of our improved the we of and Beauty Beauty segment, care our operating rate closure retention existing grown. first also In steadily our win to our have new have Closure home we care business business. closure Order our

reasons focusing these was opportunities reminder, one intensely areas X closures the a more on under As in of brought roof. we

both growth, achieved by of segment, of sales. SG&A points with improved share our meaningful improvement per raised expenses accomplishments double-digit margin target X ROIC across percentage as very adjusted double-digit line, each the many increased EBITDA significant long-term growth reduced Overall, XX%, growth, top range percentage filled with increase XXXX earnings within and year and a an after and pivotal a on was bottom an focus earnings

margins in target into turn, focus we will, our EBITDA cost management, to continue us which our on and range. In long-term disciplined will growth expand XXXX, help

Our will reduce sales. a expenses as as percentage of key focus to cost management continue efforts SG&A a remain we

important I we that to our took company realigned helping are to We Looking XXXX, beauty closer strategy also at efforts simplifying be several to all bringing would and steps propel our on closures like back under are critical the executing operationally customers, our roof. now. the segment forward. and to These company to touch one

expansions actions regions. and operations continue We our new manufacturing India. States, and China the We invest state-of-the-art reduction sites as in initiated to United in capacity with all as France, in restructuring well cost

XXXX. in drive utilization example, actions these realized segment, second closure with our asset of will to For continue the half benefits in

capital with key growth, capabilities, X And especially large was online, worldwide. key company a technologies on role XXXX in partnerships continue to the adding X of talent coming and play our focused projects by while organic growing acquisitions and

Aptar had improving We patient a from the extended will and our in outcomes. with digital demonstrate studies Chiesi productive partnership COPD, conduct Digital Health perspective. to that asthma which of the positive U.S. year effect health in for clinical help

solutions, with contract across recently agreement a company indications help will us opportunity in Health health to This enterprise XX their several and scope initial countries. covers and Biogen, biotechnology the also Digital of global neurology an details announced multiyear broaden Aptar also customers be The not operate their release agreement signed right digital develop leading to commercialize solutions. immunology the press of the after and our this ways The in capabilities, this digital solutions. will we our monetize only supporting to can and own deploy call. build but deploy health our

talk and competitiveness about Asia wanted of a to pump operations signed development venture our exciting to a increase in an with We the recently joint agreement beyond. manufacturer. also I China-based

end-to-end in which Aptar acquire have manufacturing in cost-effective a agility broadly. to the market pump agreement, partnership complete the more access will of the go-to-market Through the further in faster and local China Asian a region, company. more profitability of partnership, this part increase will chain, all stake and our XX% As supply we will

partnership to expect dispensing this regional also for health We care leveraging explore certain systems. consumer

cost that alternatives. building can and be high us used Additionally, and we machine quality, to investment capabilities competitive have globally provide will access will capital better mold with

also the Asia, across needed will These access growing a will to is of much consumer manufacturing capabilities. that partnership capabilities growth consumer the demand give help middle-class anodization us driving meet our profitable is is us regional Finally, completion be of which each segments. to later to will and more expected XXXX, details. to across time transaction close we disclose subject of at able satisfaction conditions various in and The

launches unidose GLP-X an Now molecule indication. another treatment system few elastomeric highlight overdose pharma Aptar's recently delivery of recently product is a opioid and the nasal Aptar's launched for recent let me our for innovations rescue existing featured X. space, on the In on launched. Slide new device are components a shown

customizable interchangeable fragrance is skin fragrance. prestige also product. dispensing featured Europe, our is our new Turning Saint Laurent facial care on pump the And Yves for In L'Oreal and to a Beauty. pump new premium solution

In the the on closures brands. have China new we market in the for a coffee Cephei segment, Gongfu and technology Tea

with with the the powder dispense bottle, protection the user quality the be science, technology closure. of materials protects ready push active closure a powder from technology dispensing just our powder separate until the is until used. into it the is active our the example of the activates combining great to water solution Our to while our polymer a This

the #XX places Newsweek us of both We to women, companies X% responsible lineup. pivoting most recognition top Forbes ranked companies the which on companies ranked sustainability, the are Forbes Newsweek's world's for from we Now the in And during #XX America's and receive to top proud XXX among quarter. us ranked.

the turn and Before $XXX details quarter shareholders me let dividends to shareholder repurchase XXX,XXX to for through XXXX. $XX.X Bob, over We on to over the returns further over shares I call million X, million. share for summarize returned of

of paying to year anniversary Bob. listed call and that, increased completed celebrated We New an total will With turn I dividend Stock Exchange XXth over also as our a our XXth the annual York company.

Stephan, morning, I X, summarize everyone. Slide you, to good Thank and like would the on quarter. Starting

core translation America. sales This reported in and systems to a sales in growth currency included approximately X%. of Latin fragrance grew proprietary primarily strong for Our Pharma's delivery benefit due Europe and continued dispensing solutions Therefore, X%, increased demand drug X%.

over $X.XX, EPS. prior fourth a on As Slide the X, earnings of adjusted year's adjusted shown reported per is we XX% which share increase quarter

by During the adjusted all $XXX X from in achieved year's we margins prior quarter, which driven expanding fourth of segments. XX% million, increased quarter EBITDA the by

the of quarter. details for segment some to Turning the by

core segment's from approximately delivery increased XX%, especially of drug X% growth our increased came in the Pharma proprietary volumes, sales systems. Our

Looking core sales Prescription at delivery sales XX%, dispensing in increased technologies the allergic Pharma drug segment therapeutics. by continued due systems, market our strong for medicines, for nervous rhinitis to dosing system primarily proprietary and and central emergency for demand

this components increased helped sales the sales the comparisons driven sales Demand due for that eye saline rinse prior continues core XX%, for used categories basically in Consumer Injectables core biologics grow, and nasal care, over were quarter. to down to and difficult elastomeric decongestants. flat quarter. higher solutions for by offset fourth were other year Healthcare nasal

Materials Active decreased Science our XX%. core to Solutions, sales turning Additionally,

fourth core experienced growth in nonrecurring Excluding also sales the probiotics, contributed the the products Lower over X%. quarter which kits in of to of decline at-home COVID-XX last sales sales. on the XXXX, for of rapid years used demand our couple decreased test

XX%, a EBITDA from improvement strong prior adjusted was The improvement margin X-point driven by Pharma's margin was mix. product year. primarily

decreased sales our the X% Turning segment. quarter. Beauty to in Core

facial segment be of Fragrance used offset lower to lower applications. by in sales market, strong, sales in to sales were the at beauty care Europe but skin core products America. Looking primarily continued X% beauty due in North sales by decreased our

lower to in demand regions. with focus The adjusted quarter across improvement XX% sales Europe. of positive Home due net America was demand segment's items. Care our was on management, This all continued restructuring margin Care cost decreased and and in sales a Personal due onetime decreased core North both for actions to the X% margin core XX%. the lower impact EBITDA

and due well The XX% drinks. and fields Europe Asia declined North core the market Care sports X% core customers costs to looking sales closures, infant regions and year's lower decreased for of was the quarter. sales X% due Closure prior The increased sauces sales at decline sales through higher demand as of quarter water, compared XX%. lower with driven core the across year's our America resin core all as to by decreased Beverage in prior passing in healthy the bottled for compared Personal sales by segment's volumes. lower to sales condiments nutrition. sales with for and When concentrates to food

more pass-through America, resin in North experienced than we While in market. we improved offset volumes, increases saw this Latin volume and America the particularly

X%. segment's and home In our XX%. the This cost same adjusted care, management. was productivity year, fourth sales and X-point over improvement margin a health around beauty, represents primarily EBITDA includes core last which to care category, due decreased The period

Pharma was total CapEx our Our for $XX spend majority the QX million, going with segment. XXXX to

with by capital to of targeted expansion projects X capacity injectables completed large Two of XXXX. our be expansion end our now are online the

total our of the X majority spend, quarter, injectables CapEx projects made the up XX% capacity For capital our expansion. to with large the about allocated

ago X compared $X.XX, and our $X.XX year-to-date earnings adjusted cover which per and up comparable rates. our and X% performance to X a XX% year Slides including growth show core were sales exchange share,

Reflecting and our injectables despite and line environment on XXXX, with growth good the top Aptar finished implementation. in a and difficult adjusted America EBITDA North year expansion ERP

We also a that continue took fixed will focus costs, our reduce steps XXXX. to in

a the $XXX for million XXXX, from operations In was in $XXX million cash flow million. record capital cash Free earnings management. due and $XXX year, to from working improved up XXXX flow was

strong on our come the that portion due. a from neutralize paying us coming impact rates allowed rising Our debt has expense by had cash any our flow of down to interest

XXXX. million or in to depreciation Reported approximately $XXX expense amortization $XX million and X% increased

of range XX.X% per to unrealized Moving restructuring first anticipate and $X.XX continue quarter XX, to the XX.X%. of tax range the and which share, earnings adjusted in our fair outlook estimated the $X.XX expect acquisition changes rate per share. we equity the first summarizes quarter momentum is any Slide strong investments for be in expenses, costs value to first The our for excluding to to quarter,

We expecting year. compared an currencies to to the are impact have prior not

to We currently $XXX estimate be $XXX and to XXXX depreciation million. for between amortization million

expect $XXX of toward We to the million, segment. net our XXXX, and between majority our capital be $XXX with grants allocated million of any government capital expenditures in Pharma

in strong leverage to us in a of ratio have the to opportunities to continue and form with of continue approximately return value continue balance we sheet to and allows dividends X.X, pursue business, share which a shareholders closing, In to repurchases. strategic the invest

closing approximately In quarter, comments for At in shareholders, to will provide to to repurchased move few $XX XX,XXX cash Stephan we dividend million shares totaled this addition payments which approximately million. time, we the Q&A. $XX our before a

In first Thank we quarter. on to the XXXX, you, and this strong we solid a very delivered Bob. in momentum year with XXXX, build results starting intend

for systems, which biologics. spurred quarter demand as as proprietary well be drug farmers components will already double-digit for core growth delivery the of saw growth the by quarter in first franchise Our elastomeric our X XXXX sales

segment anticipate expect for had expenses to We quarter and Closure of core from dispensing the in North our progressive of Beauty the a as continued and last reducing on XXXX which year. we several market, steps for also and also We of demand priority sales remains took our percentage fragrance We growth XXXX. benefit key reducing a sales. technologies, margins, our SG&A fixed and X remain double-digit American recovery our cost focused expand manufacturing to in that

technologies where We solutions. attractive, with markets we our serve an emphasis sustainable rapidly differentiation on growing create through

and user We regulatory are our a to our partner our end expertise customers trusted because of focus.

focus management position on market prudent our cost line. bottom while advantaged growth, line benefits Our enables our top

With ahead open would year up your for that, year. a are We start call the and the excited expect energized the of questions. to I strong like for and

[Operator of Baird. Ghansham the comes of Instructions] Panjabi So our line from first question

off, growth in it guess core was subvertical even X% quarter. the let's specific or with XQ say, worse than And -- you your first Did line plan? pharma? to come pharmaceutical XX% to third thought internal above better quarter in I the the of sort on and in which the essentially specific if versus, fourth sales

Yes. Look, pool the or broad-based. with our systems. proprietary delivery Clearly, of allergic delivery nasal just But to to emergency do is be overall, continue continues impressed well. rhinitis growth medicines drug we really with the

it's So tick maybe really that was better, a broad-based. but

had for driver you're this of market and your relative that cetera. supporting one, share to class in then terms capacity has that for with clearly growth additions, Okay. biologics, you've et including a elastomers in historical obviously, GLP-X, And the How trended of elastomers? drugs share

it And clearly, needle you track are out the a And plunger. don't space. is pens, and injectors, good have those shield. there those good a But more are then we really much a injectable And way. SKUs any major track of on track What market the as reminder We as we very know smaller broadly you market in drugs the said but auto X continue the project Yes. our for that do auto-injectors than feel much leader. the about to have we of as and we have you share, before, pipeline we built for prospects. there, still really and application

question. finally then for And Okay. just the third

much How given EPS more as onwards. should year-over-year difficult more a on comparisons comparisons Just fully? I of think quite starting sort for are the in going about quarter. you've obviously, to the to growth more second we get XQ, but difficult earnings bit profile again, guidance unfolds the be mean, are year

productive. with areas the It's really Look, productivity strong in plan costs, in plants, have Increasing on we Europe. operating executing September capacity. ensuring done you bringing haven't that Yes. we we in in like by more often in shared we're the where attacking of history our leverage of the really company

to not have growth faster disconnected really line. line, ambition. top bottom but be double-digit Bottom remains will than the the a line intent certainly, bit the quite top So growth our is EPS our from line grow

of digits year, that delivery that same strength facility our but systems was XXXX, we the and even saw the ramp-up I to The the other very Maybe have business in the from Europe, not injectables the was we whether of in at America business pockets expected strong side implementation. weakness, nonetheless. the fragrance of new could and or grow, did this with Yes. that growing our add, continue it's right? throughout to we was the the the drug consumer that course, and of of Ghansham, goods with North X saw is because X double year, ERP pace, good One proprietary

with that non-repeat what the and take You QX, situation an America, that's in North in comes and a the where saw of improving confidence gradually injectables in in. we

to example, mean half benefits that middle the reductions progresses. in the second into down the just flow you France And example. X it's see I the of year. closures in year, we the that, X in only are of will cost the These still P&L of the year as start the just shutting facility and will

of question of line from America. next comes George Our the Bank of Staphos

on a day. I good to you're hope start the

Just piggybacking maybe Ghansham's on question.

me. expect we in for in for for still question we seeing growth target what And that core we'll pharma expect Should margin range beauty First should expansion now? both your and growth? XXXX, given see right closures you're

ranges. its -- to means to designed that That's to long-term company consumer-facing are within find And point range teams to our we have this its And George, energized the good normalize efforts. the expect point. ideas and taking we work question, So culture. target productivity productivity X% their really and the pharma target to of additional making additional getting to and of starting the their in on and root staying are is have yes, your businesses say And opportunities, and but yes, our a whole increase to certainly in pride to second progress I XX%. it's margin all growth, become

target think you from is exiting standpoint? do it... you're margin Stephan, range Or your maybe the is in a year

depending the make it, progress going profitability. paint not and it I'm we're line on that the target growth, North corner. on top certainly how in see polymer ranges, the I've in recovery should we America does learned to and our be Yes, in continue myself and but to

items you did say around Bob? there? some expectations I right, hear there know about Okay. Can just return we'll you and you are in but making a that you're why to China? Did that turn share again. last try bit beauty? Kind the said investment I'll of cost that, one-off much, some actually, one, in over you it fair. that And I color My be can't share talk you can

Yes.

then the X the and Let first come me back Bob second take on one.

have we've we've serve we really very but across gaps on mentioned collaborated in fundamentally, to a I a with of we earlier, prices competitiveness. out of The and We're Asia. not company number for industrial serve steps making of executing increase world. a Chinese footprint is that for done really filling competitiveness in some in have and supply that China, living some our investment new as it's will and we well regionally see the it time us X to So this. This consumers, are a China, now in important, minority the chains only consumers in we that our

to And particular, designing and capability in it's that capability complementary additional some dispensing that's molds, highlight an I last integrated have, anodizing least, that's of dispensing very are manufacturing equipment, what impossible and have. would some important products, additional that -- solutions. get not building products integrated new for we metal what it's complementary we And almost have to and additional to to building for capability approvals

So will we're what our disclose but when respecting partners can disclose close, detail to in lot find wishes, we the only in K . we a more you

the impacting, dating claim facility positively to we the close onetime our our inertization France. on happy to insurance on report out point we're back items to George, that able were in fire And our and

it for roughly Beauty. quarter. is up say, devaluation some that's which we us, about a had an in All negative let's from perspective in in quality the Argentina $X that great netted was anticipated. items not huge million the behind a positive popped were And in other to, all, So quarter that unforeseen now The then news.

line the Rizzo from of Jefferies. comes Daniel question of next Our

a which getting with manufacturer? region, the given if a there's I working to was with wondering just a Just you're protecting in JV, exciting. happening in China back what's IP with local concern sounds

the China Look, we've in since been mid-'XXs. operating

and this a partner to I it's manage really we're the are it we North depends. we reroute expanding just supplies their actually analogy, the of at to supply do the local getting risks, also supply IP more in and more customers complete quite are chain, America and U.S. really In case, our more that experienced of accessing lot conditions, mean and from So by of want making I the more competitive. some competitive Mexico and our And chain how near-shoring technology think and in capacity and competitiveness improving as in of we

our capabilities supply chain expanding more to we're So the in U.S. competitive. Mexico make

just kind similar concept, really it's of broader based. So

they when cash X heavy program? getting of productivity then XXXX the productivity with that the were the And And end is the to doing? Okay. towards should think you're for kind for to restructuring costs, done? what the One, and ever already Or going be cost the a the where questions. two, of is just end restructuring of going we is it lot lifting and

Yes.

execute When you guided that's about the we roughly and basically, plan. on and 'XX. don't into will contributing do of you line kind in terms But see rate to thumb, because speak, things of we rule ideas, we have we severance on that. now for restructuring And 'XX guidance if costs in have people. as law you're can that savings yes, social the much the costs these And meaning on So a give by annual X:X well talking course, Europe, bottom about we of in of what those. get hopper the additional to Xx

Europe, are activities centers in Asia. streamlining themes Eastern reducing talent some France. big Mexico in in down And shutting closure in into moving and factories like the global factories, facility The labor,

themes will time at So we when disclose we and are ideas continue. And additional have those ideas, will them as ready. we the new

Instructions] next of of [Operator line E comes the question Alexander Our from Wells Fargo.

XXXX versus in provide you guys or are improvements about last or the pharma pipeline. . seeing know This guess I when on path guys of any that you from that's I out your conversion [indiscernible] projects you Day have new ask laid terms September. that the Can any maybe update? is commercialization in in you of guys Alex back a for to want kind Investor I updates for

how pipeline. come depends in Those put new they a product, of then, things we to product 'XX, And out maybe record of value of year as the tried And of pipeline complicated, the launches. and those it course, course, coming terms in describe We value what a usually product we pipeline. projects going pipeline equal basis, launch longer the of of things in in a we and you out we had, launches. are When things bit the said Alex. the Sure, no measure has a on out build. in new pipeline pipeline what multiyear a risk-adjusted and do that's of the well how into that of marketplace the come that's were is when

have see mechanics, actually feel very target the the we on -- launches it if are -- consumer-facing about we the that's So project for as doesn't growing good pharma. pipeline we you another the with the And see it's very in why want although Incidentally, 'XX. given same record also long-term the with that, feel more front we market reason but why order opportunities. comfortable we book, foot we in raised the

pharma Okay. as I guess, your last if would don't know be you portfolio? can -- you of And you part I if how can, much biologics but could,

back our little came but really to have were project. don't good for a means by detail, the equal what us that The give really but otherwise, projects the look that for and pandemic they partner a which to said that do that been going tested sense particular biologics that we everybody. new a technical We capability bit. leader, Yes. in is conclusion companies I'm being in And as biologics us especially are market to they the has

in growing made $XXX North significant well. to capacity, we is -- the But China, led pipeline we're in additional and biologics investments plus quite million the has plus America. that in build-out us So an not our acquisition

the other that say the you are do The other pipeline to So a the for That confidence have well. -- shrinking. anything end that pipeline we very overall doesn't is continues pipeline. gives sense the in markets

I And in you turn but the I'll like in and any strength between fragrances think packagers, you last of Okay. strength over. are talking what's color -- of guys more it portfolio are in do companies question, share just European consumers can beauty segment, you kind weakness Europe, demographics about difference and talking a continued is there? it is -- entire guess, on consumer or X of driving kind other that -- some In kind -- that seems the

as of weakness what's And and we part in up and when Sure. Care in around that the actually terms consumed tend do products is to in fragrance end what What in those sell look we in Europe, that Home in of a reminder, Europe, we see world. Personal to record Care. you Europe some

there, So the signaling around market, globally fragrance only we're and not and Europe goes fragrance in -- what's because the the on. so that happening loans world but LVMH and consumer

different, weakness in and expect into thing us hear from activity it's what companies you continues our we see when indeed, our of about into that is closure X% range launch X% that of So kind for for talk that the the growth experience. fragrance signal experienced consolidated not results results. customers, to gets that business while consumer other that except our a and pockets we our we same fragrance, more in fragrance beauty kind And of we

Mr. waiting back Tanda would questions at for conference remarks. like to As there are no time, additional over to call the closing hand the I

you. Thank Great.

the pandemic enhanced execution put that the work of in kicked So many to factories company year and are call successful than to bit. marketplace. off And year are in being with out out It's and during the our me now the XXXX. a we as Again, by much and capabilities our our end let a assuming businesses stronger coming are initiatives are a very all really we ago projects closing the fruition. of

on you EPS gains, line this talked double-digit the ensuring Day line trajectory. strong that very both at and our And faster in about, grows on as shared productivity than plan on line top September, we the us Investor focus we and we are keeping executing the that last have a and the ambitious top bottom with growth

we enter pipelines have strong order book. XXXX, So and as a growing we

momentum the end to pockets regional markets. of as we see weakness expect about, We we economic some of continue. in though, our Even just talked

mid-flight, underway, 'XX. 'XX and so keep number the the ended We productivity to and speak. throughout line of year also into to they a bottom And cost well efforts adding will with reduction

to becoming And culture then innovation point last eager it's our find teams and really to addition root a We had our opportunities. that, just in just in of taking week, a are the leadership productivity like and sustainability. company in event additional pride

footprints increasing joint in in and for are North Mexican our with of now that North Europe, regional our we market. capacity expanding about competitiveness Asia the the in a America, American actions including talked including We venture

invest in allows sheet us future and balance strong continue to to Our investments. growth productivity

and of and record partnerships bite-sized to we solid return track against well As developed bolt-on fans those to you have a acquisitions funds as know, are shareholders. as deliver

you consider coming the it's and grow, injectable repeat the proprietary all pipeline sure puts otherwise. growth So our will of in and ERP strong it's takes overall and drug biologics for to target, the our year after growth inside systems even pharma 'XX target delivery period, strong the issue will from benefiting a for and continue when remain the not

out clients. Biogen. operate as press we minutes We this or win start coming digital release to for so, the for we health XX health more didn't well digital more digital with and have is our that but in talk our about project solutions health, bodes business Again,

abate. year grow Elsewhere, after And fragrance We pulling will of growth. also the double-digit to destocking is North anticipate America continue Asia to nicely.

SG&A bit down. fixed costs whether really coming pull is China in it's stronger recovery much to starts India our manufacturing a are expenses, While or more muted.

up, that more for we forward all in bodes joining. discuss on the with to sum and Thanks detail for beyond, So that when you XXXX look road. well you and

Ladies today's that and great Have a rest gentlemen, of your call. conference day. concludes

lines. your disconnect now may You